Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease

被引:31
作者
Eltayeb, S
Sunnemark, D
Berg, AL
Nordvall, G
Malmberg, Å
Lassmann, H
Wallström, E
Olsson, T
Ericsson-Dahlstrand, A
机构
[1] Karolinska Inst, Dept Med, Neuroimmunol Unit, SE-17176 Stockholm, Sweden
[2] RA CNS & Pain Control, AstraZeneca R&D Sodertalje, Dept Mol Sci, SE-15185 Sodertalje, Sweden
[3] AstraZeneca R&D Sodertalje, Safety Assessment, Dept Pathol, SE-15185 Sodertalje, Sweden
[4] AstraZeneca R&D Sodertalje, Dept Chem, SE-15185 Sodertalje, Sweden
[5] RA CNS & Pain Control, AstraZeneca R&D Sodertalje, Dept Lead Discovery, SE-15185 Sodertalje, Sweden
[6] Univ Vienna, Inst Brain Res, A-1090 Vienna, Austria
[7] Karolinska Inst, Dept Med, Rheumatol Unit, SE-17176 Stockholm, Sweden
关键词
multiple sclerosis; chemokines; macrophages; demyelination; inflammation; receptor;
D O I
10.1016/S0165-5728(03)00264-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have studied the role of the chemokine receptor CCR1 during the effector stage of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in DA rats. In situ hybridization histochemistry revealed local production of the CCR1 ligands CCL3 (MIP-1alpha) and CCL5 (RANTES), as well as large numbers of CCR1 and CCR5 expressing cells within inflammatory brain lesions. A low-molecular weight CCR1 selective antagonist potently abrogated both clinical and histopathological disease signs during a 5-day treatment period, without signs of peripheral immune compromise. Thus, we demonstrate therapeutic targeting of CCR1-dependent leukocyte recruitment to the central nervous system in a multiple sclerosis (MS)-like rat model. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 46 条
  • [1] AMOR S, 1994, J IMMUNOL, V153, P4349
  • [2] Chemokines in the CNS: plurifunctional mediators in diverse states
    Asensio, VC
    Campbell, IL
    [J]. TRENDS IN NEUROSCIENCES, 1999, 22 (11) : 504 - 512
  • [3] CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
    Balashov, KE
    Rottman, JB
    Weiner, HL
    Hancock, WW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6873 - 6878
  • [4] Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression
    Baranzini, SE
    Elfstrom, C
    Chang, SY
    Butunoi, C
    Murray, R
    Higuchi, R
    Oksenberg, JR
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (11) : 6576 - 6582
  • [5] Berger T, 1997, LAB INVEST, V76, P355
  • [6] MONOCYTE-MACROPHAGE DIFFERENTIATION IN EARLY MULTIPLE-SCLEROSIS LESIONS
    BRUCK, W
    PORADA, P
    POSER, S
    RIECKMANN, P
    HANEFELD, F
    KRETZSCHMAR, HA
    LASSMANN, H
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (05) : 788 - 796
  • [7] Multiple sclerosis
    Compston, A
    Coles, A
    [J]. LANCET, 2002, 359 (9313) : 1221 - 1231
  • [8] The CC chemokine MIP-1α induces a selective monocyte infiltration following intradermal injection into nonhuman primates
    Didier, PJ
    Paradis, TJ
    Gladue, RP
    [J]. INFLAMMATION, 1999, 23 (01) : 75 - 86
  • [9] Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression
    Fischer, FR
    Santambrogio, L
    Luo, Y
    Berman, MA
    Hancock, WW
    Dorf, ME
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2000, 110 (1-2) : 195 - 208
  • [10] Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis
    Flügel, A
    Berkowicz, T
    Ritter, T
    Labeur, M
    Jenne, DE
    Li, ZX
    Ellwart, JW
    Willem, M
    Lassmann, H
    Wekerle, H
    [J]. IMMUNITY, 2001, 14 (05) : 547 - 560